Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's good you can see the group effort. Good to be careful Leo...
Well my CA 19-9 and CEA levels are okie dokie again...Scans today. All the rest of blood work is ok.
Don't read conspiracy nuts and don't be one. It's ugly.
Just another lame excuse to defend Missling. Wall Street is totally corrupt. Pharma is totally corrupt. The FDA is totally corrupt. Healthcare is totally corrupt. Doctors are poisoning people. They’re all conspiring against Anavex to keep their billions of revenues from poisons flowing. Missling alone is fighting the good fight against the powers aligned against him. He’s the true hero, tirelessly working for the benefit of suffering patients and shareholders.
Have I got that right?
Agree. I once read an exert of his touting Leqembi.
PW I now nothing about leaving in a huff. I do know his current position with Eisai. Global Vice President. If you don't think that Biogen/Eisai joint venture won't take a run at us for license or buyout you are nuts. I think that is why Missling mentioned it at the ASM. Prior to that buyout was not on the table. If for some reason you think Misslings stock and performance is higher than Hampel you are nuts.
We are in this for the money
Hampel with the backing of the venture could make this explode
Especially with autophagy.
mrp, he is similar to your boy, HH, and Aisen ... tied strongly to the amyloid concept. He probably thought he s/h/b the lead person on SAB and left in a huff. Good riddance.
There is no doubt that ALL System(s) are exploitable.
Madoff, Enron, Bankman-Fried, etc will forever exist.
And the lesser scaled culprits are more brazen than smart.
IF you do not feel there is a PROPER solution to what
you believe is actively affecting your investments.....
Well I have left many a Poker table because of perceived "teams"
manipulating a fair game. Doesn't mean I have quit playing.
The standard bromide:
If you look around the table and don't see a fool/loser....it is you.
I await re-entry to NVDA (its pre split April SP may not be in play, but late May likely is)
as well as AVXL (choose your price points, but $12 is a pipe dream prior to at least November)
with much more potentially at risk in NVDA.
As they say...It is a Market.
And Bas...I have never felt more proud to receive an emoji such as yours (considering the source).
The third paragraph probably most applicable to you.
But yet we just need MORE data to overcome the this, right? Lol!
Wrong, like you understand we need NDA’s and MAA’s prepared for submittal to start the “clock” for approval. I cant wait for this process to unfold and to see shorts try to unwind their position. There needs to be a move made where MM’s need to account for EVERY share similar to the Nasdaq uplisting. These theives operate without regard for human suffering. Hell, they would steal from their own mother. Our short term plan of Rett Syndrome NDA for submission was an unlucky miss but fortunately we have the capital to get past the Alzheimer’s MAA submittal, others not so lucky.
Keep the faith Guzzi.
But of course....speaking of courses, I'm off to one.
Alarmingly just like when AVXL release news huh?
This is the first part of a must read article...
And the stock loses over 8%. Sure hope we don't get any news like that. I know they are in a cash crunch but still....
The remaining holdout WGTers like you will eventually realize and accept that Missling is a failed CEO and an impediment to success. I think there’s been more than enough evidence to date that the guy is in over his head but some are slow to recognize it.
This guy Missling has done nothing positive for shareholder value and yet some don’t seem to mind. It seems more important to protect Missling (and their own egos) than to make money. Too bad so many have missed out on the greatest bull market in decades by sitting with too much AVXL.
Congratulations to them.
I recall Anavex was doing a PD trial many years ago, I wonder what happened there?
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
https://finance.yahoo.com/news/annovis-bio-announces-data-phase-120000626.html
Let's just ride the gathering wave !
George,
Again, The Science is real. The issue is having a non qualified CEO at the top of the organization being overpaid and having on the job training. Very disappointed Cummings has left the SAB
Talon38 ".Anavex prophylactically started at 40!!!!"--how about thinking "approval first" before considering prophylactic !!!!!!! Getting a bit ahead of yourselves !!!!!!
power--"When did Dr. Cummings l"-was wondering the same !!! Too busy to work with us ??? Too many irons in the fire !! We also lost Michael Kornhauser FWIW---Anavex employee (formerly employed at Hammond Care under Dr.MacFarlane)---not enough to keep him busy down under ????
Well Publicized, I will as usual await other(s) to spark
the next volume bounce off less than $4 low before re entry.
Won't be this week, though.
I do think the channel is rising as 10K trades have remained
relatively cheap from an allocation basis.
And 5K shares is almost a buy in for 20/40 NLH.
If you go back a few years in your thinking Xena, it was; "No patent protection and their funding sources were wrong!" Now, years later, we're funded with patent protection. It's a never-ending cycle with a group here. Arm chair qb's...When these people get their back against the wall health wise, I hope they remember your posting as to how to bring their health back to somewhat normalcy when Dr's screw it up.
No news today, no news tomorrow, definitely no news Thursday, and they never release news on a Friday - so no news this week. At least we have a holiday so we know there will be ONE day this week this POS won't go down.
“ Tred, it took only 1 or 2 placebo (or dosed) caretakers to fudge the numbers for a few $$$,$$$ to sink the "p" number as they knew their charge(s) would receive blarcamesine in the OLE for as long as they want once the trial was over ... Australia AD trial being the forerunner.”
Well, being that you went there, lol, it was public knowledge that dizziness was regularly associated with being on the active drug. Maybe they titrated them up slower or had them on a lower dose? Im not sure.
Agree wholeheartedly......Anavex prophylactically started at 40!!!!
Institutional ownership. Anavex 38%, LLY 84%, BIIB 93%, SAVA 24% less shortly due to, GE 77%, WELL 96%, AXSM 83% + 17% insiders retail near zero.
John k9uwa
Thanks Tom if we again get to $3.80 or below I'll buy more shares.
John k9uwa
Thanks. It's nice that independent researchers are adding meat to the bone for us.
Just been looking into that rival NYC biotech that George mentioned - Axsome ($81, 2 billion market cap). They combine some sort of Sigmar1 agonist with an NMDA inhibitor and got great results and FDA approval for major depression therapy. Works in a week, remission in two weeks - which certainly seems to blow away the competition (it's a pill), but on sale for a year and only brings in 50 million a quarter in revenue. Funny they haven't partnered it. Like our stuff it seems to help in all sorts of CNS diseases. We combine Sigmar1 with a muscarinic something or other, just as they combine with NMDA inhibitor. There's a third company that has a Sigmar1 thing that George mentioned while ago...doesn't seem to work that great. Hopefully we can do as well as this Axsome stuff. Certainly we can do better marketing and partnering it than Axsome has done so far with their thing!
https://www.biospace.com/employer/544380/axsome-therapeutics/
Hon - that is magical thinking to support your short position.
IT AIN'T GONNA WORK !!!!
When did Dr. Cummings leave the SAB?
My apologies if discussed before as I missed it.
"In March, the U.S. Food and Drug Administration (FDA) issued a revised draft guidance to help drug companies develop medication to treat cases of early Alzheimer’s disease that “occur before the onset of overt dementia.”
Could be perfect timing for Anavex
https://www.theepochtimes.com/health/should-alzheimers-be-treated-before-it-becomes-symptomatic-experts-weigh-in-5616383?utm_source=goodeveningnoe&src_src=goodeveningnoe&utm_campaign=gv-2024-07-01&src_cmp=gv-2024-07-01&utm_medium=email&est=AAAAAAAAAAAAAAAAZOc8dxYb6djJ5LwB8GZWBn1BtHFmWXjh8PCDQuhsH40%3D
And WGT were saying it's cheaper to run trials in Australia and that Misleading is very smart. I agree with the smart comment: he knows how to kick the can and make money for himself. He's not here to get the drug to the finish line.
Another conspiracy theory. The clown doesn't even know how to design trials. Maybe he designed them this way on purpose to kick the can...Never underestimate crooks.
Tred, it took only 1 or 2 placebo (or dosed) caretakers to fudge the numbers for a few $$$,$$$ to sink the "p" number as they knew their charge(s) would receive blarcamesine in the OLE for as long as they want once the trial was over ... Australia AD trial being the forerunner.
I kind of believed in the guy the first five years the last five not so much and the last three and a half not at all I think we would have been flying a long time ago if he wasn't around
Don't forget the sigma-1 receptor activator as a treatment for Major Depressive Disorder from Axsome Therapeutics AXS-05, which was approved almost 2 years ago by the FDA .
Has anyone in your life ever complied with one of your demands?
Screaming not emphasis Caps were a nice touch.
If you are going to use a link from another poster for your statistics,
You may wish to quote them accurately let alone understand the insider ownership significance of the numbers.
“ That is some high-level conspiracy thinking. How much do you think "they" paid the placebo group to do their bidding for them?”
No, I did not precisely convey my point. In our case they “got lucky” is what I should have said in that we had an over active placebo group. Who would of thought it to be the case? We had Dr. Kaufman on board and Rett Syndrome.org on board….., very unlucky on our part as our drug is safe, well tolerated in a liquid form, and many received symptomatic relief. We should have been well on our way to submitting an NDA by now for Rett Syndrome and climbing into the 1.5-2 billion MC upon approval.
Sorry for the confusion.
The company is aware and has interest in A-273 as a heart benefit. AFIB is a common occurrence.
https://www.anavex.com/post/anavex-life-sciences-announces-notice-of-allowance-for-u-s-patent-application-anavex-2-73
“This new use of ANAVEX®2-73 (blarcamesine) will be exceptionally important for Alzheimer’s disease patients because the advanced age of these patients make them also more susceptible to heart disease,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, adding: “We are extremely pleased with the continued development of the patent portfolio for ANAVEX®2-73 (blarcamesine). When it issues, this new patent will fortify our robust patent portfolio relating to ANAVEX®2-73 (blarcamesine), and further demonstrate our strong overall commitment to protecting the innovation and commercial opportunity of our product portfolio”.
When I refer to the dwindling number of WGTers who still refuse to face the reality that Missling isn’t up to the task, you are one of the people on the list. You’ll come around eventually, just like so many others have.
What do sigma-1 receptors do in depression?
Sigma-1 receptor (S1R) is a unique multi-tasking chaperone protein in the endoplasmic reticulum. Since S1R agonists exhibit potent antidepressant-like activity, S1R has become a novel target for antidepression therapy. With a rapid and sustained antidepressant effect, ketamine may also interact with S1R.Dec 14, 2023
"Big money gets in one way or another, and cheap. When their normal tools don't work they resort to other measures like an SEC investigation etc. In our case we had an over active placebo group that did their bidding for them and down we went."
That is some high-level conspiracy thinking. How much do you think "they" paid the placebo group to do their bidding for them? (Especially since by corruptly tanking the trial, those parents actively harmed their own sick children; "they" must have paid a lot to them and also to the CRO to break the blinding of the placebo group.)
Awesome, then I WILL STOP....
Not seeing any studies having been done on whether boosting Sigmar1 has beneficial effects on heart disease. A deficit of Sigmar1 has shown an increase in damaging heart health factors in two studies here referred to, but nothing regarding the heart effects of boosting Sigmar1. The implication is it would be beneficial to boost it in a patient with low Sigmar1 - i.e. aging patients generally who do lose Sigmar1 as they age. That would be a good trial to do ad a good indication to farm out to big pharma for sure.
An overactive placebo group did their bidding for them? Does this also explain why our CEO hasn’t made a self-imposed deadline in 9 years? Or makes asinine and arrogant claims about only needing 3 trial participants to measure a drug’s effectiveness? Boy, Missling really looks like a genius after the Rett readout, once he removes the egg yolk from his face.
You are delusional, so this board welcomes you with open arms.
The preponderance of evidence is that Anavex is in a very good position. It may not be WGT. However, it is looking pretty darn good.
Big money gets in one way or another, and cheap. When their normal tools dont work they resort to other measures like an SEC investigation etc. In our case we had an over active placebo group that did their bidding for them and down we went. This is the case for MANY if not ALL baby bio’s, just look around and dont be such naive nanny’s needing your bottle refilled.
In our case as we sit the 37% insty vs 59% retail is the biggest concern for the HF’s. Add to that that Dr. Missling does not do secondaries and you have an all out assault on our stock, same as other companies only they know they need funding so down they squeeze. We arent desparate like others so we will be just fine.
All that said I really find comfort in our consistent sizable bankroll and the stage of submittals we currently sit at.
I say go pound sand to all those naysayers out there!
Tred
I'll stop if you will stop with the you expect ... every day. Deal?
Followers
|
1074
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
464602
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |